AgomAb Therapeutics (NASDAQ:AGMB) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of AgomAb Therapeutics (NASDAQ:AGMB) from a hold rating to a sell rating in a report issued on Saturday morning.

A number of other equities research analysts have also commented on AGMB. B. Riley Financial initiated coverage on AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price target for the company. HC Wainwright started coverage on shares of AgomAb Therapeutics in a research note on Monday, June 22nd. They issued a “buy” rating and a $35.00 target price for the company. Five analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.00.

AgomAb Therapeutics Price Performance

Shares of AGMB opened at $13.68 on Friday. AgomAb Therapeutics has a 52 week low of $8.75 and a 52 week high of $17.82. The business’s 50 day moving average is $12.59.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share for the quarter. Analysts expect that AgomAb Therapeutics will post -1.77 EPS for the current year.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.